|

Golidocitinib Clinical Trials

6 actively recruiting trials across 1 location

Also known as: AZD4205, DZD4205

Pipeline

Phase 1: 1Phase 2: 2Phase 3: 2Phase 1/2: 1

Top Sponsors

  • Sun Yat-sen University1
  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine1
  • Peking University Cancer Hospital & Institute1
  • M.D. Anderson Cancer Center1
  • Henan Cancer Hospital1

Indications

  • Cancer6
  • Peripheral T Cell Lymphoma5
  • NSCLC (Advanced Non-small Cell Lung Cancer)1
  • Lung Cancer1

Other5 trials

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Phase 3
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
Phase 1
Go-CHOP as the Frontline Therapy for PTCL
Phase 2
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Phase 1/2
Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
Phase 3

Houston, Texas1 trial

A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study

MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.